Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer

BACKGROUND: For patients with locally advanced gastric cancer (LAGC) after D2 gastrectomy, the survival benefits of receiving adjuvant chemoradiotherapy versus adjuvant chemotherapy are unclear. This study aimed to compare the 5- and 7-year overall survival (OS) in the two groups and to identify whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Gui-Fen, Zhang, Hai-Ge, Liu, Juan, Chen, Yi-Xing, Xiao, Han, Wang, Xue-Fei, He, Jian, Zeng, Zhao-Chong, Sun, Jing, Liu, Tian-Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612289/
https://www.ncbi.nlm.nih.gov/pubmed/31303797
http://dx.doi.org/10.2147/CMAR.S204887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612289/
https://www.ncbi.nlm.nih.gov/pubmed/31303797
http://dx.doi.org/10.2147/CMAR.S204887

Ejemplares similares